These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

306 related items for PubMed ID: 17283191

  • 1. Species-specific differences in the susceptibilities of biofilms formed by Candida bloodstream isolates to echinocandin antifungals.
    Choi HW, Shin JH, Jung SI, Park KH, Cho D, Kee SJ, Shin MG, Suh SP, Ryang DW.
    Antimicrob Agents Chemother; 2007 Apr; 51(4):1520-3. PubMed ID: 17283191
    [Abstract] [Full Text] [Related]

  • 2. Paradoxical effect of Echinocandins across Candida species in vitro: evidence for echinocandin-specific and candida species-related differences.
    Chamilos G, Lewis RE, Albert N, Kontoyiannis DP.
    Antimicrob Agents Chemother; 2007 Jun; 51(6):2257-9. PubMed ID: 17438060
    [Abstract] [Full Text] [Related]

  • 3. In vitro effects of micafungin against Candida biofilms on polystyrene and central venous catheter sections.
    Seidler M, Salvenmoser S, Müller FM.
    Int J Antimicrob Agents; 2006 Dec; 28(6):568-73. PubMed ID: 17101265
    [Abstract] [Full Text] [Related]

  • 4. Biofilm Production and Antibiofilm Activity of Echinocandins and Liposomal Amphotericin B in Echinocandin-Resistant Yeast Species.
    Marcos-Zambrano LJ, Gómez-Perosanz M, Escribano P, Zaragoza O, Bouza E, Guinea J.
    Antimicrob Agents Chemother; 2016 Jun; 60(6):3579-86. PubMed ID: 27021323
    [Abstract] [Full Text] [Related]

  • 5. In vitro susceptibilities of Candida spp. to caspofungin: four years of global surveillance.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2006 Mar; 44(3):760-3. PubMed ID: 16517851
    [Abstract] [Full Text] [Related]

  • 6. Global surveillance of in vitro activity of micafungin against Candida: a comparison with caspofungin by CLSI-recommended methods.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2006 Oct; 44(10):3533-8. PubMed ID: 17021079
    [Abstract] [Full Text] [Related]

  • 7. Multicenter surveillance of species distribution and antifungal susceptibilities of Candida bloodstream isolates in South Korea.
    Jung SI, Shin JH, Song JH, Peck KR, Lee K, Kim MN, Chang HH, Moon CS, Korean Study Group for Candidemia.
    Med Mycol; 2010 Jun; 48(4):669-74. PubMed ID: 20392145
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. National surveillance of species distribution in blood isolates of Candida species in Japan and their susceptibility to six antifungal agents including voriconazole and micafungin.
    Takakura S, Fujihara N, Saito T, Kudo T, Iinuma Y, Ichiyama S.
    J Antimicrob Chemother; 2004 Feb; 53(2):283-9. PubMed ID: 14688039
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Micafungin triggers caspase-dependent apoptosis in Candida albicans and Candida parapsilosis biofilms, including caspofungin non-susceptible isolates.
    Shirazi F, Kontoyiannis DP.
    Virulence; 2015 Feb; 6(4):385-94. PubMed ID: 26065323
    [Abstract] [Full Text] [Related]

  • 12. Differential in vitro activity of anidulafungin, caspofungin and micafungin against Candida parapsilosis isolates recovered from a burn unit.
    Ghannoum MA, Chen A, Buhari M, Chandra J, Mukherjee PK, Baxa D, Golembieski A, Vazquez JA.
    Clin Microbiol Infect; 2009 Mar; 15(3):274-9. PubMed ID: 19210699
    [Abstract] [Full Text] [Related]

  • 13. Candida bloodstream infections: comparison of species distribution and resistance to echinocandin and azole antifungal agents in Intensive Care Unit (ICU) and non-ICU settings in the SENTRY Antimicrobial Surveillance Program (2008-2009).
    Pfaller MA, Messer SA, Moet GJ, Jones RN, Castanheira M.
    Int J Antimicrob Agents; 2011 Jul; 38(1):65-9. PubMed ID: 21514797
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. In vitro activities of anidulafungin against more than 2,500 clinical isolates of Candida spp., including 315 isolates resistant to fluconazole.
    Pfaller MA, Boyken L, Hollis RJ, Messer SA, Tendolkar S, Diekema DJ.
    J Clin Microbiol; 2005 Nov; 43(11):5425-7. PubMed ID: 16272464
    [Abstract] [Full Text] [Related]

  • 16. Species-specific and drug-specific differences in susceptibility of Candida biofilms to echinocandins: characterization of less common bloodstream isolates.
    Simitsopoulou M, Peshkova P, Tasina E, Katragkou A, Kyrpitzi D, Velegraki A, Walsh TJ, Roilides E.
    Antimicrob Agents Chemother; 2013 Jun; 57(6):2562-70. PubMed ID: 23529739
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. In vitro effectiveness of anidulafungin against Candida sp. biofilms.
    Rosato A, Piarulli M, Schiavone BP, Catalano A, Carocci A, Carrieri A, Carone A, Caggiano G, Franchini C, Corbo F, Montagna MT.
    J Antibiot (Tokyo); 2013 Dec; 66(12):701-4. PubMed ID: 24022607
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 16.